Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine is a synthetic small molecule with the chemical formula C15H14N2O and a molecular weight of approximately 238.28 g/mol. It features a pyrrolopyridine core substituted at the third position with a (meta-)methoxybenzyl group. This compound has been identified as an experimental inhibitor of fibroblast growth factor receptor 1 (FGFR1), suggesting potential utility in modulating FGFR signaling pathways relevant to cancer and other proliferative diseases. However, there are no approved indications or advanced clinical trials reported for this molecule as of June 2025.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine.